(MedPage Today) — SAN FRANCISCO — The adjuvant combination of pembrolizumab (Keytruda) and belzutifan (Welireg) significantly improved disease-free survival (DFS) in patients with clear cell renal cell carcinoma (ccRCC) after nephrectomy versus…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
